Dr. Gonzalez-Martin on the Results of the PRIMA Trial in Ovarian Cancer
Antonio Gonzalez-Martin, MD, co-director, Department of Medical Oncology, Clinica Universidad de Navarra, discusses the results of the phase III PRIMA trial in advanced ovarian cancer.
Antonio Gonzalez-Martin, MD, co-director, Department of Medical Oncology, Clinica Universidad de Navarra, discusses the results of the phase III PRIMA trial in advanced ovarian cancer.
Data presented at the 2019 ESMO Congress demonstrated that frontline maintenance therapy with niraparib (Zejula) improved median progression-free survival (PFS) by 5.6 months versus placebo in patients with newly diagnosed, advanced platinum-sensitive ovarian cancer.
Investigators conducted a hierarchical analysis of patients with homologous recombination deficiency (HRD), which, if positive, would prompt analysis of the overall population, says Gonzalez-Martin. Among patients with HRD, the median PFS was 21.9 months with niraparib versus 10.4 months with placebo (HR, 0.43; 95% CI, 0.50-0.76; P <.001). The median PFS in the overall population was 13.8 months in the niraparib arm versus 8.2 months in the placebo arm, which translated to a 38% reduction in the risk of progression or death with the addition of the PARP inhibitor (HR, 0.62; 95% CI, 0.50-0.76; P <.001).
